After several decades, therapeutic cancer vaccines now show signs of efficacy and potential
to help patients resistant to other standard-of-care immunotherapies, but they have yet to …

Cancer development and its response to therapy are regulated by inflammation, which
either promotes or suppresses tumor progression, potentially displaying opposing effects on …

Regulatory T (Treg) cells, an immunosuppressive subset of CD4+ T cells characterized by
the expression of the master transcription factor forkhead box protein P3 (FOXP3), are a …

Cancer immunotherapies, such as immune checkpoint blockade and chimeric antigen
receptor (CAR) T cell therapy, have transformed clinical oncology. However, limited patient …

In the past decade, bacteria‐based cancer immunotherapy has attracted much attention in
the academic circle due to its unique mechanism and abundant applications in triggering the …

The success of immunotherapy in oncology underscores the vital role of the immune system
in cancer development. Regulatory T cells (Tregs) maintain a fine balance between …

Live regulatory T cells (Treg cells) suppress antitumor immunity, but how Treg cells behave
in the metabolically abnormal tumor microenvironment remains unknown. Here we show …

Regulatory T (Treg) cells suppress inflammation and regulate immune system activity. In
patients with systemic or organ-specific autoimmune diseases or those receiving …

CD25 is expressed at high levels on regulatory T (Treg) cells and was initially proposed as a
target for cancer immunotherapy. However, anti-CD25 antibodies have displayed limited …

It is generally accepted that metabolism is able to shape the immune response. Only
recently we are gaining awareness that the metabolic crosstalk between different tumor …